PTC India Financial Services Ltd. Share Price

Update for investors of

Gland Pharma Secures Major CDMO Agreement with Potential of $90–100 Million in Annualized Revenue

Gland Pharma has entered into a strategic Manufacturing and Supply Agreement (MSA) with a leading, undisclosed global pharmaceutical company to serve as an end-to-end Contract Development and Manufacturing Organization (CDMO) for sterile injectable products. Key Deal Highlights: Scope of Work: Comprehensive "one-stop" solution covering technology transfer, process development, scale-up, validation, and long-term commercial manufacturing. Product Portfolio: 55 Stock Keeping Units (SKUs) spanning both oncology and non-oncology products, delivered in complex presentations including Vials, Lyophilized (Lyo), Ampoules, and Pre-filled Syringes (PFS). Capacity: Production will be distributed across three of Gland Pharma’s manufacturing sites. Financial Impact: Estimated annualized revenue potential of USD 90–100 million once fully commercialized. Timeline: Technology transfer is expected to be completed within two years, with revenue generation slated to commence in Calendar Year 2029. Strategic Rationale: CDMO Expansion: This agreement solidifies Gland Pharma’s transition into a full-service, integrated CDMO partner, moving beyond traditional contract manufacturing to include high-value development and technology transfer services. Focus on Complex Formulations: The inclusion of oncology products and pre-filled syringes highlights a strategic focus on technically demanding, higher-margin sterile injectables rather than conventional low-margin generics. Outlook: While revenue realization is deferred until 2029, this multi-year agreement provides exceptional long-term top-line visibility and ensures high capacity utilization across Gland’s manufacturing network. It strongly validates the company’s global quality standards and development capabilities, positioning it for sustained growth in the highly lucrative global CDMO market.

Lupin Limited Latest Updates

Lupin Receives USFDA Approval for Interchangeable Biosimilar Ranluspec

Lupin Limited has secured US FDA approval for Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar referencing Genentech’s Lucentis, on June 4, 2026. Key Highlights: Unique Market Position: Ranluspec is the only interchangeable biosimilar ranibizumab approved in the US that is available in both vial and pre-filled syringe (PFS) presentations. Dosage & Strengths: Approved in 0.3 mg and 0.5 mg strengths across both the vial and PFS formats. Clinical Indications: Indicated for treating multiple retinal conditions, including neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema, diabetic retinopathy, and macular edema following retinal vein occlusion. Mechanism of Action: Functions as a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A). Strategic Significance: Commercial Advantage: The "interchangeable" designation allows for pharmacy-level substitution (subject to state laws), driving rapid market penetration. Furthermore, offering both vial and PFS formats gives ophthalmologists maximum flexibility, providing Lupin a distinct competitive edge over rival biosimilars. Portfolio Deepening: The approval significantly expands Lupin’s biosimilars portfolio and solidifies its leadership in the complex biologics segment. Manufacturing Validation: Reinforces the company's scientific rigor and advanced capabilities in complex biologics development and large-scale manufacturing. Outlook: With the US ophthalmology biosimilars market being highly lucrative, Ranluspec's dual-presentation and interchangeable status position Lupin to capture significant market share from the originator (Lucentis) and other competitors.

PTC India Financial Slips After Weak Results Reaction